Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023
- 1National Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia
- 2The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia
Abstract
BACKGROUND: Modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine is used globally for disease prevention. Real-world safety data following co-administration of MVA-BN with other vaccines is limited.
AIM: To characterise the adverse event profile of MVA-BN given alone or concomitantly with other vaccines using data from Australia’s active vaccine safety surveillance (AusVaxSafety).
METHODS: Individuals (≥ 18 years) who received MVA-BN between 30 August 2022 and 20 April 2023 at sentinel AusVaxSafety surveillance sites and registered via QR code were surveyed on days 7 and 14 post-vaccination regarding adverse events following immunisation (AEFI), medical review by a healthcare professional and impact on daily activities. Analyses included participants who completed both surveys. Outcomes were compared by administration route, dose and concomitant vaccination status.
RESULTS: Among 10,943 participants (response rate: 46%; 97% male), 200 (1.8%) received at least one concomitant vaccine. Across 14 days, AEFI rates were comparable or lower in concomitant recipients following intradermal administration (alone: 56% (Dose 1), 36% (Dose 2) vs concomitant: 53% (Dose 1), 32% (Dose 2)) and subcutaneous administration (alone: 49% (Dose 1), 32% (Dose 2) vs concomitant: 28% (Dose 1) and 24% (Dose 2)). Medical review was uncommon (0–2.7%). Impact on daily activities was low across groups (6% vs 3.5%), with most symptoms lasting ≤ 1 day.
CONCLUSION: The frequency and severity of AEFIs within 14 days post-vaccination were similar between concomitant and non-concomitant group. These findings provide preliminary, exploratory evidence supporting the safe co-administration of MVA-BN with other adult vaccines, primarily in adult men, and may help inform future immunisation policy and public health recommendations.
Related
- Receptor-guided engineering of oncolytic vaccinia creates a synthetic support niche for off-the-shelf NK cell therapy
- Morphological changes in the eyelid following modified rotational suturing combined with lower eyelid margin fixation for the correction of congenital lower eyelid epiblepharon
- The bisbenzimide compound ridinilazole has antiviral activity against vaccinia and mpox viruses.
- Interleukin-21 expressing oncolytic vaccinia virus elicits systemic anti-tumor immune response and synergizes with immunotherapies
- The selection for cidofovir-resistant mutant vaccinia viruses is inhibited by coinfecting cidofovir-sensitive wildtypes
BibTeX
@article{nguyen2026shortterm,
title = {{Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023}},
author = {Thuy Nguyen and Kristine Macartney and Nicholas Wood and Lucy Dawes and Lucy Deng},
journal = {Eurosurveillance},
year = {2026},
month = nov,
doi = {10.2807/1560-7917.es.2026.31.44.2600181},
url = {https://doi.org/10.2807/1560-7917.es.2026.31.44.2600181},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Short-term adverse events following modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine with and without concomitant vaccines, Australia, 2022 to 2023
AU - Thuy Nguyen
AU - Kristine Macartney
AU - Nicholas Wood
AU - Lucy Dawes
AU - Lucy Deng
PY - 2026
DA - 2026/11/05
JO - Eurosurveillance
DO - 10.2807/1560-7917.es.2026.31.44.2600181
UR - https://doi.org/10.2807/1560-7917.es.2026.31.44.2600181
AB - BACKGROUND: Modified vaccinia Ankara–Bavarian Nordic (MVA-BN) mpox vaccine is used globally for disease prevention. Real-world safety data following co-administration of MVA-BN with other vaccines is limited. AIM: To characterise the adverse event profile of MVA-BN given alone or concomitantly with other vaccines using data from Australia’s active vaccine safety surveillance (AusVaxSafety). METHODS: Individuals (≥ 18 years) who received MVA-BN between 30 August 2022 and 20 April 2023 at sentinel AusVaxSafety surveillance sites and registered via QR code were surveyed on days 7 and 14 post-vaccination regarding adverse events following immunisation (AEFI), medical review by a healthcare professional and impact on daily activities. Analyses included participants who completed both surveys. Outcomes were compared by administration route, dose and concomitant vaccination status. RESULTS: Among 10,943 participants (response rate: 46%; 97% male), 200 (1.8%) received at least one concomitant vaccine. Across 14 days, AEFI rates were comparable or lower in concomitant recipients following intradermal administration (alone: 56% (Dose 1), 36% (Dose 2) vs concomitant: 53% (Dose 1), 32% (Dose 2)) and subcutaneous administration (alone: 49% (Dose 1), 32% (Dose 2) vs concomitant: 28% (Dose 1) and 24% (Dose 2)). Medical review was uncommon (0–2.7%). Impact on daily activities was low across groups (6% vs 3.5%), with most symptoms lasting ≤ 1 day. CONCLUSION: The frequency and severity of AEFIs within 14 days post-vaccination were similar between concomitant and non-concomitant group. These findings provide preliminary, exploratory evidence supporting the safe co-administration of MVA-BN with other adult vaccines, primarily in adult men, and may help inform future immunisation policy and public health recommendations.
SN - 1025-496X
SN - 1560-7917
ER -